Related Experiment Video
Updated: May 18, 2026
05:03
Accessing Early Differentiation of Virus-Specific Follicular Helper CD4+ T Cell in Acute LCMV-Infected Mice
Published on: April 26, 2024
What we are learning on HTLV-1 pathogenesis from animal models
Madeleine Duc Dodon1, Julien Villaudy, Louis Gazzolo
1Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon Lyon, France.
Frontiers in Microbiology
|September 13, 2012
Summary
Human T cell leukemia virus type 1 (HTLV-1) causes aggressive cancers and inflammatory diseases. Humanized mouse models are revolutionizing the study of HTLV-1 infection and the development of new therapies.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Human T cell leukemia virus type 1 (HTLV-1) is linked to adult T cell leukemia/lymphoma and inflammatory conditions.
- Animal models have been crucial for understanding HTLV-1 transmission and pathogenesis.
- Humanized mouse models offer advanced in vivo investigation of viral infections.
Purpose of the Study:
- To review the role of animal models, particularly humanized mouse models, in studying HTLV-1.
- To highlight the potential of these models for understanding HTLV-1 pathogenesis and developing therapies.
Main Methods:
- Utilized various animal models, including small (rabbits, rats, mice) and large (monkeys) animals.
- Employed immunocompromised mouse strains reconstituted with a human immune system (HIS).
- Studied HTLV-1-infected humanized HIS mice that develop lymphomas.
Main Results:
- Animal models have advanced knowledge of HTLV-1 transmission, viral proteins, and infected cells.
- Humanized HIS mice develop HTLV-1-associated lymphomas, enabling study of proviral clonality.
- These models facilitate research into leukemogenic and immunopathogenic processes.
Conclusions:
- Humanized mouse models represent a significant advancement in studying HTLV-1 in vivo.
- Ongoing improvements in humanized models will accelerate drug testing and targeted therapy development for HTLV-1 diseases.
